WE ARE TARGETING PAIN AT ITS SOURCE
VIRPAX Pharmaceuticals specializes in developing novel and proprietary drug delivery systems across various pain indications in order to enhance compliance
and optimize the ability of each non-addictive product in our pipeline.
Our novel drug compounds, improved drug-delivery systems, and drug-releasing technologies are focused on advancing non-opioid and non-addictive pain management treatments allowing healthcare professionals to target a patient’s pain at its source. Our products cover a range of applications from postoperative pain to the treatment of acute and chronic pain.
VIRPAX has global rights to a patented metered-dose topical spray film delivery technology for musculoskeletal pain.
VIRPAX has worldwide rights to a patented injectable “local anesthetic” liposomal hydrogel technology for postoperative pain management.
VIRPAX has global rights to a proprietary patented Molecular Envelope Technology (MET) that uses an intranasal device to deliver enkephalin via nanoparticles for the management of acute and chronic pain, including pain associated with cancer.
VIRPAX® Pharmaceuticals is a publicly held company (Nasdaq: VRPX) located in Berwyn, PA and is focused on the development and commercialization of its non-addictive pipeline.
Prescribers, regulators, and patients all seek non-addictive treatment options to combat the opioid epidemic. VIRPAX will utilize our drug delivery technologies to develop a pipeline of proprietary prescription candidates for commercialization.
OUR MISSION
Our mission is to improve widely-used and newly-developed non-addictive pain medicines by optimizing their delivery systems.
OUR VISION
We are focused on becoming the global leader in non-addictive pain management by developing and commercializing innovative pharmaceutical products.
DEVELOPING OPTIONS
Our purpose is to provide healthcare professionals and patients with effective solutions to manage postoperative, acute and chronic pain, while helping prescribers facilitate better pain management outcomes worldwide.
FUTURE GROWTH POTENTIAL
We believe that this topical metered-dose spray technology could provide a pathway for additional proprietary spray formulations going forward. These additional indications include estrogen levels, Alzheimer’s disease, dementia, Parkinson’s disease, neuropathic issues, and acute and chronic pain.
EXPERIENCED
EXECUTIVE LEADERSHIP
ROBUST
PIPELINE
REINVENTING PAIN RELIEF
CHANGING THE WAY WE MANAGE PAIN
VIRPAX’s proprietary pipeline is well positioned to meet the unmet needs in a multi-billion dollar market.
Image is for illustration purposes only
Epoladerm™ nonclinical studies have demonstrated improved drying times and less messy handling compared to topical gels/ointments. It’s an invisible application; therefore, more aesthetically appealing. It’s pliable application allows for optimized use on joints and other contours of the body.
VIRPAX will also introduce its proprietary Probudur™, a single injectable liposomal gel local anesthetic for postoperative pain management. Probudur will be the only liposomal gel bupivacaine with 96 hours of postoperative pain control; 24 hours longer than any other liposomal bupivacaine.
The FDA indicated that if Probudur can meet its clinical end points in two or more clinical trials, the results of those studies could be reflected in a labeling claim.
Envelta™ is being studied to manage acute and chronic pain, including pain associated with cancer, without the concerns of dependence, respiratory depression, and tolerance compared to morphine.
